Nuclear accumulation of E-Cadherin correlates with loss of cytoplasmic membrane staining and invasion in pituitary adenomas

Journal of Clinical Endocrinology and Metabolism

Volumn 94, Issue 4, 2009, Pages 1436-1442

  Elston, Marianne S ^a,b,c   Gill, Anthony J ^b,c   Conaglen, John V ^e   Clarkson, Adele ^c   Cook, Raymond J ^d   Little, Nicholas S ^d   Robinson, Bruce G ^a,b   Clifton Bligh, Roderick J ^a,b   McDonald, Kerrie L ^a,b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c ROYAL NORTH SHORE HOSPITAL   (Australia)

^d Ryde and North Shore Hospitals   (Australia)

^e UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; BETA CATENIN; UVOMORULIN;

ADULT; AGED; ARTICLE; CANCER INVASION; CELL MEMBRANE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOPLASM; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; HYPOPHYSIS ADENOMA; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; SEQUENCE ANALYSIS;

EID: 65249114762     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2008-2075     Document Type: Article

References (88)

1. Asa SL, Ezzat S 1998 The cytogenesis and pathogenesis of pituitary adenomas. Endocr Rev 19:798-827
2. Daly AF, Rixhon M, Adam C, Dempegioti A, Tichomirowa MA, Beckers A 2006 High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. J Clin Endocrinol Metab 91:4769-4775
3. Umbas R, SchalkenJA, Aalders TW, Carter BS, Karthaus HF, SchaafsmaHE, Debruyne FM, Isaacs WB 1992 Expression of the cellular adhesion molecule E-cadherin is reduced or absent in high-grade prostate cancer. Cancer Res 52:5104-5109
4. Behrens J, Mareel MM, Van Roy FM, Birchmeier W 1989 Dissecting tumor cell invasion: epithelial cells acquire invasive properties after the loss of uvomorulin-mediated cell-cell adhesion. J Cell Biol 108:2435-2447
5. Frixen UH, Behrens J, Sachs M, Eberle G, Voss B, Warda A, Lochner D, Birchmeier W 1991 E-cadherin-mediated cell-cell adhesion prevents invasiveness of human carcinoma cells. J Cell Biol 113:173-185
6. Qian ZR, Li CC, YamasakiH,Mizusawa N, Yoshimoto K, Yamada S, Tashiro T, Horiguchi H, Wakatsuki S, Hirokawa M, Sano T 2002 Role of E-cadherin, α-,β-, and γ-catenins, and p120 (cell adhesion molecules) in prolactinoma behavior. Mod Pathol 15:1357-1365
7. Xu B, Sano T, Yoshimoto K, Yamada S 2002 Downregulation of E-cadherin and its undercoat proteins in pituitary growth hormone cell adenomas with prominent fibrous bodies. Endocr Pathol 13:341-351
8. Nishioka H, Haraoka J, Akada K 2003 Fibrous bodies are associated with lower GH production and decreased expression of E-cadherin in GH-producing pituitary adenomas. Clin Endocrinol (Oxf) 59:768-772
9. Yamada S, Ohyama K, Taguchi M, Takeshita A, Morita K, Takano K, Sano T 2007 A study of the correlation between morphological findings and biological activities in clinically nonfunctioning pituitary adenomas. Neurosurgery 61:580-584; discussion 584-585
10. Qian ZR, Sano T, Yoshimoto K, Asa SL, Yamada S, Mizusawa N, Kudo E 2007 Tumor-specific downregulation and methylation of the CDH13 (H-cadherin) and CDH1 (E-cadherin) genes correlate with aggressiveness of human pituitary adenomas. Mod Pathol 20:1269-1277
11. Kawamoto H, Mizoue T, Arita K, Tominaga A, Eguchi K, Kurisu K 1997 Expression of epithelial cadherin and cavernous sinus invasion in human pituitary adenomas. J Neurooncol 34:105-109
12. Yoshiura K, Kanai Y, Ochiai A, Shimoyama Y, Sugimura T, Hirohashi S 1995 Silencing of the E-cadherin invasion-suppressor gene by CpG methylation in human carcinomas. Proc Natl Acad Sci USA 92:7416-7419
13. Howng SL, Wu CH, Cheng TS, Sy WD, Lin PC, Wang C, Hong YR 2002 Differential expression of Wnt genes, β-catenin and E-cadherin in human brain tumors. Cancer Lett 183:95-101
14. Chetty R, Serra S, Asa SL 2008 Loss of membrane localization and aberrant nuclear E-cadherinexpression correlates with invasion in pancreatic endocrine tumors. Am J Surg Pathol 32:413-419
15. Chetty R, Serra S 2008 Membrane loss and aberrant nuclear localization of E-cadherin are consistent features of solid pseudopapillary tumour of the pancreas. An immunohistochemical study using two antibodies recognizing different domains of the E-cadherin molecule. Histopathology 52:325-330
16. Serra S, Salahshor S, Fagih M, Niakosari F, Radhi JM, Chetty R 2007 Nuclear expression of E-cadherin in solid pseudopapillarytumors ofthe pancreas. JOP 8:296-303
17. Salahshor S, Naidoo R, Serra S, Shih W, Tsao MS, Chetty R, Woodgett JR 2008 Frequent accumulation of nuclear E-cadherin and alterations in the Wnt signaling pathway in esophageal squamous cell carcinomas. Mod Pathol 21:271-281
18. Han AC, Soler AP, Tang CK, Knudsen KA, Salazar H 2000 Nuclear localization of E-cadherin expression in Merkel cell carcinoma. Arch Pathol Lab Med 124:1147-1151
19. Hardy J 1979 Transsphenoidal microsurgical treatment of pituitary tumours. In: Linfoot J, ed. Recent advances in the diagnosis and treatment of pituitary tumours. New York: Raven Press; 375-388
20. Elston MS, Gill AJ, Conaglen JV, Clarkson A, Shaw JM, Law AJ, Cook RJ, Little NS, Clifton-Bligh RJ, Robinson BG, McDonald KL 2008 Wnt pathway inhibitors are strongly down-regulated in pituitary tumors. Endocrinology 149:1235-1242
21. Rozen S, Skaletsky HJ 2000 Primer3 on the WWW for general users and for biologist programmers. In: Misener S, Krawetz SA, eds. Bioinformatics methods and protocols: methods in molecular biology. Humana Press, Totowa, NJ, pp 365-386
22. Brooks-Wilson AR, Kaurah P, Suriano G, Leach S, Senz J, Grehan N, Butterfield YS, Jeyes J, Schinas J, Bacani J, Kelsey M, Ferreira P, MacGillivray B, MacLeod P, Micek M, Ford J, Foulkes W, Australie K, Greenberg C, LaPointe M, Gilpin C, NikkelS,GilchristD,HughesR,JacksonCE,MonaghanKG,OliveiraMJ,Seruca R, Gallinger S, Caldas C, Huntsman D 2004 Germline E-cadherin mutations in hereditary diffuse gastric cancer: assessment of 42 new families and review of genetic screening criteria. JMed Genet 41:508-517
23. GuilfordP, Hopkins J, Harraway J, McLeod M, McLeod N, Harawira P, Taite H, Scoular R, Miller A, Reeve AE 1998 E-cadherin germline mutations in familial gastric cancer. Nature 392:402-405
24. Berx G, Cleton-Jansen AM, Nollet F, de Leeuw WJ, van de Vijver M, Cornelisse C, van Roy F 1995 E-cadherin is a tumour/invasion suppressor gene mutated in human lobular breast cancers. EMBO J 14:6107-6115
25. Tziortzioti V, Ruebel KH, Kuroki T, Jin L, Scheithauer BW, Lloyd RV 2001 Analysis of β-catenin mutations and α-, β-, and γ-catenin expression in normal and neoplastic human pituitary tissues. Endocr Pathol 12:125-136
26. Ferber EC, Kajita M, Wadlow A, Tobiansky L, Niessen C, Ariga H, Daniel J, Fujita Y 2008 A role for the cleaved cytoplasmic domain of E-cadherin in the nucleus. J Biol Chem 283:12691-12700
27. Jordan S, Lidhar K, Korbonits M, Lowe DG, Grossman AB 2000 Cyclin D and cyclin E expression in normal and adenomatous pituitary. Eur J Endocrinol 143:R1-R6
28. Hibberts NA, Simpson DJ, Bicknell JE, Broome JC, Hoban PR, Clayton RN, Farrell WE 1999 Analysis of cyclin D1 (CCND1) allelic imbalance and over expression in sporadic human pituitarytumors. Clin Cancer Res 5:2133-2139
29. 1443-1450 Cortisol Inactivation by 11β-Hydroxysteroid dehydrogenase-2 May Enhance Endometrial Angiogenesis via Reduced Thrombospondin-1 in Heavy Menstruation
30. Mick Rae
31. Amirah Mohamad
32. Deborah Price
33. Patrick W. F. Hadoke
34. Brian R. Walker
35. J. Ian Mason
36. Stephen G. Hillier
37. Hilary O. D. Critchley
38. Centre for Reproductive Biology and Centre for Cardiovascular Science, University of Edinburgh, The Queen's Medical Research Institute, Edinburgh EH16 4TJ, United Kingdom
39. Division of Reproductive and Developmental Sciences, Centre for Reproductive Biology, University of Edinburgh, The Queen's Medical Research Institute, 47 Little France Crescent, Edinburgh EH16 4TJ.
40. Current address for M.R.: Napier University, 10 Colinton Rd., Edinburgh EH10 SDT, United Kingdom.
41. hilary.critchley@ed.ac.uk
42. 10.1210/jc.2008-1879
43. Context: Heavy menstrual bleeding (HMB; menorrhagia) impairs quality of life for women and requires medication or surgery. Because glucocorticoids inhibit angiogenesis in other organs, we hypothesized that endometrium of women with HMB is subject to decreased local glucocorticoid exposure and enhanced angiogenesis, thereby increasing menstrual bleeding. Design: Endometrium was collected from 29 women with menstrual complaints. Menstrual blood loss was measured by alkaline-hematin assay (n = 12, > 80 ml (HMB); n = 17, < 80 ml). Quantitative RT-PCR for thrombospondin-1 (TSP-1) and glucocorticoid- metabolizing enzymes, 11β-hydroxysteroid dehydrogenases-1 and -2 (11βHSD1,2) was performed. Glucocorticoid effects on endometrial stromal cells and uterine endothelial cells (UECs) were determined. RNA interference studies in UECs examined the effect of TSP-1 ablation on cortisol action. Results: Secretory phase endometrium mRNA levels for the cortisol inactivating enzyme 11βHSD2 were higher [3.78 ± 1.29 vs. 1.40 ± 0.6 (arbitrary units), P < 0.05], whereas TSP-1 mRNA was lower [0.40 ± 0.13 vs. 1.66 ± 1.02 (arbitrary units), P < 0.05] in women with HMB. In cultured endometrial stromal cells and UECs, cortisol increased TSP-1 expression. Both cor- tisol and TSP-1 inhibited new vessel formation in endometrial explants embedded in Matrigel. In UECs cortisol inhibition of tube-like structure formation was blocked by small interfering RNA (siRNA) against TSP-1 (25 ± 2.5% cortisol inhibition with scrambled siRNA vs. 0% cortisol inhibition with TSP-1 siRNA inactivation, P<0.01). Conclusions: Enhanced inactivation of cortisol by 11βHSD2 in endometrium from women with HMB may explain reduced TSP-1 levels and hence endothelial cell dysfunction and abnormal angiogenesis. Inhibition of 11βHSD2 may be a rational novel therapy for heavy menstrual bleeding. Copyright © 2009 by The Endocrine Society.
44. Hilary Critchley
45. Division of Reproductive and Developmental Sciences, Centre for Reproductive Biology, University of Edinburgh, The Queen's Medical Research Institute, 47 Little France Crescent, Edinburgh EH16 4TJ.
46. Current address for M.R.: Napier University, 10 Colinton Rd., Edinburgh EH10 SDT, United Kingdom.
47. hilary.critchley@ed.ac.uk
48. Lepine LA, Hillis SD, Marchbanks PA, Koonin LM, Morrow B, Kieke BA, Wilcox LS 1997 Hysterectomy surveillance-United States, 1980-1993. MMWR CDC Surveill Summ 46:1-15
49. National Institute for Health and Clinical Excellence (NICE) Guideline January 2007: heavy menstrual bleeding. Reference CG44. http://www.nice.org.uk/ guidance/CG44/guidance
50. Reid PC, Mukri F 2005 Trends in number of hysterectomies performed in
51. England for menorrhagia: examination of health episode statistics, 1989 to 2002-3. BMJ 330:938-939
52. Cullen W 1796 Of the menorrhagia, or the immoderate flow of the menses. In: First lines of the practice of physic. Vol III, part 1, book IV. Edinburgh: Bell, Bradfute
53. Huang KC 1993 In: The pharmacology of Chinese herbs. London, Tokyo: CRC Press; 275-278
54. Edwards CR, Stewart PM, Burt D, Brett L, McIntyre MA, Sutanto WS, de Kloet ER, Monder C 1988 Localisation of 11β-hydroxysteroid dehydrogenase-tissue specific protector of the mineralocorticoid receptor. Lancet 2:986-989
55. Funder JW, Pearce PT, Smith R, Smith AI 1988 Mineralocorticoid action: target tissue specificity is enzyme, not receptor, mediated. Science 242:583-585
56. Smith SK 2001 Regulation of angiogenesis in the endometrium. Trends Endocrinol Metab 12:147-151
57. Krikun G, Schatz F, Lockwood CJ2004 Endometrial angiogenesis: from physiology to pathology. Ann NY Acad Sci 1034:27-35
58. Rogers PA, Abberton KM 2003 Endometrial arteriogenesis: vascular smooth muscle cell proliferation and differentiation during the menstrual cycle and changes associated with endometrial bleeding disorders. Microsc Res Tech 60:412-419
59. Jabbour HN, Kelly RW, Fraser HM, Critchley HO 2006 Endocrine regulation of menstruation. Endocr Rev 27:17-46
60. Small GR, Hadoke PW, Sharif I, Dover AR, Armour D, Kenyon CJ, Gray GA, Walker BR 2005 Preventing local regeneration of glucocorticoids by 11β hydroxysteroid dehydrogenase type 1 enhances angiogenesis. Proc Natl Acad Sci USA 102:12165-12170
61. McDonald SE, Henderson TA, Gomez-Sanchez CE, Critchley HO, Mason JI 2006 11β-Hydroxysteroid dehydrogenases in human endometrium. Mol Cell Endocrinol 248:72-78
62. NoyesRW, HertigAT, RockJ1950 Datingtheendometrialbiopsy. Fertil Steril 1:3-25
63. Warner PE, Critchley HO, Lumsden MA, Campbell-Brown M, Douglas A, Murray GD 2004 Menorrhagia II: is the 80-mL blood loss criterion useful in management of complaint of menorrhagia? Am J Obstet Gynecol 190:1224-1229
64. Rae MT, Niven D, Critchley HO, Harlow CR, Hillier SG 2004 Antiinflammatory steroid action in human ovarian surface epithelial cells. J Clin Endocrinol Metab 89:4538-4544
65. Kane N, Jones M, Brosens JJ, Saunders PT, Kelly RW, Critchley HO 2008 Transforming growth factor-β1 attenuates expression of both the progesterone receptor and Dickkopf in differentiated human endometrial stromal cells. Mol Endocrinol 22:716-728
66. Iruela-Arispe ML, Porter P, Bornstein P, Sage EH 1996 Thrombospondin-1, an inhibitor of angiogenesis, is regulated by progesterone in the human endometrium. J Clin Invest 97:403-412
67. Henderson TA, Saunders PT, Moffett-King A, Groome NP, Critchley HO 2003 Steroid receptor expression in uterine natural killer cells. J Clin Endocrinol Metab 88:440-449
68. Bamberger AM, Milde-Langosch K, Loning T, Bamberger CM 2001 The glucocorticoid receptor is specifically expressed in the stromal compartment of the human endometrium. J Clin Endocrinol Metab 86:5071-5074
69. Manolis T, Lee YC, Temkin S, Hellman M, Nacharaju VL, Abulafia O 2006 NAD dependent 11β -hydroxysteroid dehydrogenase activity in human endo- metrium and endometrial tumors. Gynecol Obstet Invest 62:103-107
70. Smith OP, Jabbour HN, Critchley HO 2007 Cyclooxygenase enzyme expression and E series prostaglandin receptor signalling are enhanced in heavy menstruation. Hum Reprod 22:1450-1456
71. Lethaby A, Augood C, Duckitt K 2002 Nonsteroidal anti-inflammatorydrugs for heavy menstrual bleeding. Cochrane Database Syst Rev CD000400
72. Anteby SO, Yarkoni S, Ever Hadani P 1985 The effect of a prostaglandin synthetase inhibitor, indomethacin, on excessive uterine bleeding. Clin Exp Obstet Gynecol 12:60-63
73. SmithSK, Abel MH, KellyRW, Baird DT1981 Prostaglandin synthesis in the endometrium of women with ovular dysfunctional uterine bleeding. Br JObstet Gynaecol 88:434-442
74. Adelantado JM, Rees MC, Lopez Bernal A, Turnbull AC 1988 Increased uterine prostaglandin E receptors in menorrhagic women. Br JObstet Gynaecol 95:162-165
75. Esemuede N, Lee T, Pierre-Paul D, Sumpio BE, Gahtan V 2004 The role of thrombospondin-1 in human disease. J Surg Res 122:135-142
76. Mirkin S, Archer DF 2004 Effects of levonorgestrel, medroxyprogesterone acetate, norethindrone, progesterone, and 17β-estradiol on thrombospondin-1 mRNA in Ishikawa cells. Fertil Steril 82:220-222
77. Critchley HO, Abberton KM, Taylor NH, Healy DL, Rogers PA 1994 Endo metrial sex steroid receptor expression in women with menorrhagia. Br J Obstet Gynaecol 101:428-434
78. Krikun G, SchatzF, Taylor R, Critchley HO, Rogers PA, Huang J, Lockwood CJ 2005 Endometrial endothelial cell steroid receptor expression and steroid effects on gene expression. J Clin Endocrinol Metab 90:1812-1818
79. Flugel-Koch C, Ohlmann A, Fuchshofer R, Welge-Lussen U, Tamm ER 2004 Thrombospondin-1 in the trabecular meshwork: localization in normal and glaucomatous eyes, and induction by TGF-β1 and dexamethasone in vitro. Exp Eye Res 79:649-663
80. Leclerc N, LuppenCA, Ho VV, Nagpal S, Hacia JG, SmithE, Frenkel B2004 Gene expression profiling of glucocorticoid-inhibited osteoblasts. J Mol Endocrinol 33:175-193
81. Qian X, Wang TN, Rothman VL, Nicosia RF, Tuszynski GP 1997 Thrombospondin-1 modulates angiogenesis in vitro by up-regulation of matrix metalloproteinase-9 in endothelial cells. Exp Cell Res 235:403-412
82. Malik S, Day K, Perrault I, Charnock-Jones DS, Smith SK 2006 Reduced levels of VEGF-A and MMP-2 and MMP-9 activity and increased TNF-α in menstrual endometrium and effluent in women with menorrhagia. Hum Reprod 21:2158 -2166
83. Patel MK, Mulloy B, Gallagher KL, O'Brien L, Hughes AD 2002 The antimitogenicaction of the sulphated polysaccharide fucoidan differs from heparin in human vascular smooth muscle cells. Thromb Haemost 87:149-154
84. Gahtan V, Wang XJ, Willis AI, Tuszynski GP, Sumpio BE 1999 Thrombospondin-1 regulation of smooth muscle cell chemotaxis is extracellular signal-regulated protein kinases 1/2 dependent. Surgery 126:203-207
85. Nesselroth SM, Willis AI, Fuse S, OlsonET, Lawler J, Sumpio BE, Gahtan V 2001 The C-terminal domain of thrombospondin-1 induces vascular smooth muscle cell chemotaxis. J Vasc Surg 33:595-600
86. Lee T, Nesselroth SM, Olson ET, Esemuede N, Lawler J, Sumpio BE, Gahtan V 2003 Thrombospondin-1-induced vascular smooth muscle cell chemotaxis: the role of the type 3 repeat and carboxyl terminal domains. J Cell Biochem 89:500 -506
87. Abberton KM, Taylor NH, Healy DL, Rogers PA 1999 Vascular smooth muscle cell proliferation in arterioles of the human endometrium. Hum Reprod 14:1072-1079
88. Girling JE, Rogers PA 2005 Recent advances in endometrial angiogenesis research. Angiogenesis 8:89-99